Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan F Rodriguez

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
The Journal of Clinical Investigation|April 2, 2024
Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancerMiguel Quiralte, Arantzazu Barquín, Mónica Yagüe-Fernández, et al.
International Journal of Cancer|July 24, 2019
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaJuan M Roldan-Romero, Benoit Beuselinck, María Santos, et al.
Melanoma Research|March 29, 2023
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational studyJosé L Manzano, Juan Martin-Liberal, Luis A Fernández-Morales, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
The Journal of Clinical Investigation|April 2, 2024
Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancerMiguel Quiralte, Arantzazu Barquín, Mónica Yagüe-Fernández, et al.
International Journal of Cancer|July 24, 2019
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaJuan M Roldan-Romero, Benoit Beuselinck, María Santos, et al.
Melanoma Research|March 29, 2023
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational studyJosé L Manzano, Juan Martin-Liberal, Luis A Fernández-Morales, et al.
Pageof 4